Bayer
NEWS
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
Celmatix’s drug program works by mimicking anti-Mullerian hormone, which acts as the molecular break that keeps women from depleting their ovarian reserves too quickly.
Texas is quickly becoming a hotbed of biopharmaceutical activities, with Houston being one of the two top cities in the state that is leading the way.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.
The U.S. Food and Drug Administration approved Merck and Bayer’s heart failure drug vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, the pharma giants announced this morning.
In an interview with BioSpace, Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space.
The collaboration with Atara will focus on developing an off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
JOBS
IN THE PRESS